Incyte Corporation (INCY) The chart of INCY pop up in my chart screener, as a chart with a bullish reversal pattern called “Tripple Bottom” . The Triple Bottom Reversal is a bullish reversal pattern, Once the first bottom is created, the price reaches a peak and retraces back toward the prior support. This is when […]
Option traders making moves
Today, we detected some large moves in the option markets for multiple names we follow. As we enter the fourth quarter, we suspect this increase in frequency. ARIAD Pharmaceuticals (NASDAQ: ARIA) The February $16 puts were very active today, with over 9,000 in volume (vs open interest of only 76 contracts). One trader sold two […]
PPHM – Trade Note #1
Note: Patrick believes there is a risk this trades below $1 prior to OCT expiration if the company comes back with the analysis of what happened or the OS data from the 1st line trial is negative (which he expects) prior to that time.
ZIOP – Trading In an Uptrend Channel
Ziopharm(NASDAQ: ZIOP) In Patrick’s latest article “Smallcap Phase 3 data expected by year-end 2012” he mentions Ziopharm’s current Phase 3 trial of Palifosfamide. This Phase 3 trial, known as PICASSO 3, is testing Palifosfamide (Zymafos or ZIO-201) in addition to Doxorubicin versus Doxorubicin in front-line metastatic soft tissue sarcoma. The trial completed enrollment on June 2nd. […]
ACHN – Trade Note #1
Note: Company has an R&D day on Sept 27th and AASLD in early November — both which may increase volatility.
ASTX – Trade Note #1
Research Link: https://www.chimeraresearchgroup.com/2012/09/upcoming-events-for-nktr-astx-thld/
ONCY – Phase III Trade Strategy
Some comments from Patrick on this name: When to expect the data: Oncolytics Biotech is running a two-stage Phase III clinical trial examining REOLYSIN® in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers (REO 018). From the company’s June 20th DMC safety review, “The study design stipulates that the study […]
AMRN HZNP – Amarin’s VASCEPA and Horizon’s RAYOS receive FDA approval
Late Thursday afternoon, we learned that both Amarin (NASDAQ: AMRN) and Horizon Pharmaceuticals (NASDAQ: HZNP) separate new drug applications had been approved by the FDA. We have some insight to share on both names. With respect to Horizon, unfortunately, their future is not looking so bright. Rayos is a delayed-release formulation of low-dose prednisone. Prednisone […]
